Picture

AstraZeneca - ADDC Collaboration

The collaboration allows for ADDC members to have direct access to the AstraZeneca's library of compounds.

This collaboration between ADDC and AstraZeneca is aimed at at facilitating efforts by researchers from academia and institutions towards the discovery of novel compounds with potential pharmaceutical application.
Click here for more information

Highlighted Partnerships

The Division of Signal Transduction Therapy

A vital asset of the MRC-PPU is the Division of Signal Transduction Therapy (DSTT) which was established in 1998. This division operates as a unique collaboration between scientists in the MRC-PPU (all PIs...

Argenta and ANTABIO Announce Drug Discovery Collaboration

Argenta, a Galapagos NV (Euronext: GLPG) company that provides drug discovery services from target validation to proof of concept, announced today that it has achieved a milestone with its collaboration pa...

Evotec and Yale University to collaborate on cancer therapy

Evotec announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine. The objective of this collaboration ...

Evotec and Yale University form Open Innovation Alliance

Evotec and Yale intend to leverage first rate science performed at Yale University together with Evotec's drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases...

Senex Biotechnology

The mission of Senex Biotechnology is to discover and develop therapeutic agents to effectively treat cancer, viral diseases and age-related diseases, such as Alzheimer's, renal disease, atherosclerosis, a...

Number of Registered Partnerships

44

So Far
Therapeuitic Areas of Expertise
  • Choices
    Percentage
  • Oncology
     
    27.27%
  • Infectious Diseases
     
    11.36%
  • Neurological Disorders
     
    34.09%
  • Immunology
     
    22.73%
  • Metabolic Disorders
     
    22.73%
  • Cardiology
     
    11.36%
  • Pain
     
    4.55%
  • Other
     
    13.64%
  •  
     
Therapeutic Approaches
  • Choices
    Percentage
  • Small Molecules
     
    77.27%
  • Biologics
     
    34.09%
  • Biomarkers
     
    2.27%
  • Drug Delivery
     
    2.27%
  • Stem Cells
     
    2.27%
  • Vaccines
     
    0%
  • Antibodies
     
    9.09%
  • Other
     
    2.27%
  •